New Zepbound options aim to increase drug accessibility

In an effort to widen supply and improve access to its weight loss drug Zepbound for people who do not have insurance, Eli Lilly & Co. has introduced a new version of the medication at half the price. The drug is now available in 2.5 mg and 5 mg single-dose vials through the manufacturer’s direct-to-consumer website, costing $399 and $549 per month, respectively.

 Full Story: CNBC (8/27)